Momenta Pharmaceuticals Announces Date of Second Quarter 2015 Financial Results Conference Call and Webcast
21 juil. 2015 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., July 21, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals Announces CFO Retirement and Succession Plan
25 juin 2015 08h45 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that Rick Shea has advised the Company of his intention to step down as Chief Financial...
Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
18 juin 2015 17h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 18, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), today announced that Sandoz has initiated its U.S. launch of once daily Glatopa™ (glatiramer...
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
18 juin 2015 10h37 HE
|
Momenta Pharmaceuticals
- Decision Clears Patents for Launch of GlatopaTM, the First Generic Version of Daily COPAXONE 20 mg Approved by the FDA -
CAMBRIDGE, Mass., June 18, 2015 (GLOBE NEWSWIRE) -- Momenta...
Momenta Pharmaceuticals Announces Oral and Poster Presentations Relating to Novel Autoimmune Programs at EULAR 2015
04 juin 2015 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 4, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
01 juin 2015 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
26 mai 2015 11h07 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 26, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
19 mai 2015 19h51 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 19, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
18 mai 2015 16h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 18, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting
18 mai 2015 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 18, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...